Watch | COVID-19 Bulletin: India's First Vaccine Candidate Gets Regulatory Nod for Human Trials
Pawanjot Kaur
Real journalism holds power accountable
Since 2015, The Wire has done just that.
But we can continue only with your support.
According to media reports, the Hyderabad-based vaccine manufacturer, Bharat Biotech, has been accorded permission by the Drug Controller General of India (DCGI) to initiate Phase I & II human clinical trials for India's first vaccine candidate against COVID-19.
The vaccine has been named Covaxin and is an inactivated vaccine developed indigenously. It was developed after the National Institute of Virology, Pune isolated a strain of the SARS-CoV-2 and transferred it to the company. Human clinical trials are scheduled to start across India in July 2020.
The Wire is now on WhatsApp. Follow our channel for sharp analysis and opinions on the latest developments.